Bilateral Reduction of Diabetic Macular Edema Following Unilateral Injection of Aflibercept

Sarah N Manz and Roger A Goldberg*

Ophthalmology, Bay Area Retina Associates, Walnut Creek, CA, USA

*Corresponding Author: Roger A Goldberg, Ophthalmology, Bay Area Retina Associates, Walnut Creek, CA, USA.

Received: January 20, 2020; Published: January 29, 2020

Abstract
We report a case in which intravitreal aflibercept appeared to have effects in the contralateral, untreated eye in a patient with bilateral diabetic macular edema. A 55-year-old man with poorly-controlled insulin-dependent type II diabetes received an intravitreal injection of aflibercept in the left eye, with a plan to return the following week for treatment of the right eye. Optical coherence tomography images taken at follow-up one week later showed a marked reduction in intraretinal fluid and central retinal thickness in both eyes.

Keywords: Anti-Vascular Endothelial Growth Factor (anti-VEGF), Diabetic Macular Edema (DME), Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR), Aflibercept, Eylea, Bilateral, Ophthalmology, Retina, Case Report

Abbreviations
AMD: Age-Related Macular Degeneration; DME: Diabetic Macular Edema; SD-OCT: Spectral-Domain Optical Coherence Tomography; OD: Right Eye; OS: Left Eye; OU: Both Eyes; VEGF: Vascular Endothelial Growth Factor

Introduction
Vascular endothelial growth factor (VEGF) is a naturally occurring cell-signaling protein that promotes angiogenesis and enhances vascular permeability. Additionally, VEGF serves as an important mediator in the pathogenesis of various retinal vascular diseases including diabetic macular edema (DME). Anti-VEGF therapies are widely used to treat patients with DME. By blocking VEGF activity, vascular permeability is reduced, helping to slow the progress of macular edema and improve visual acuity [1].

Currently, three anti-VEGF agents are widely used to treat DME: bevacizumab (Avastin, Genentech), aflibercept (Eylea, Regeneron), and ranibizumab (Lucentis, Genentech). Many reports of bilateral effects following unilateral bevacizumab and ranibizumab injections can be found in the literature [2-7]. Few reports, however, have shown bilateral therapeutic effects following intravitreal aflibercept injection [8,9].

Here, we report a case in which unilateral injection of aflibercept resulted in bilateral reduction of DME as documented by spectral-domain optical coherence tomography (SD-OCT).
Bilateral Reduction of Diabetic Macular Edema Following Unilateral Injection of Aflibercept

Case Presentation

A 55-year-old male with bilateral DME was referred to a tertiary care retinal clinic for a new vitreous hemorrhage in the left eye. Corrected visual acuity was 20/300 OD and 20/300 OS. Slit lamp exam revealed early nuclear sclerotic cataracts OU, and dilated funduscopic exam was notable for clinically-significant macular edema OU, with severe non-proliferative diabetic retinopathy in the right eye, and proliferative diabetic retinopathy in the left eye with a mild vitreous hemorrhage. OCT confirmed the presence of center-involving DME OU (Figure 1a). The patient was treated with aflibercept 2 mg/0.05 mL OS that day and seen back in clinic four days later. Repeat exam and OCT showed marked improvement in the DME in both the treated left eye, and untreated right eye (Figure 1b). Visual acuity had improved to 20/200 OD and 20/250 OS.

![Figure 1: A 55-year-old male with DME OU. Spectral-domain optical coherence tomography (SD-OCT) shows prominent intraretinal fluid OU (a), which improves in both eyes 4 days after treating the left eye with intravitreal aflibercept injection (b).](image)

Discussion

Intravitreal injections enable the delivery of a relatively high dose of VEGF inhibition, with a corresponding low-dose of systemic exposure to these medications. This low systemic exposure contributes to the excellent safety profile of these medications when delivered directly into the vitreous cavity [10-12].

Although bilateral responses have been reported following both bevacizumab and ranibizumab treatment for patients with neovascular age-related macular degeneration (AMD), there appear to be more reports in DME patients [2-6,9]. This may be related to alterations in the blood-retinal barrier in diabetic retinopathy that are greater than what is seen in other retinal vascular diseases like AMD [13].

Bakbak., et al. compared unilateral intravitreal bevacizumab and ranibizumab injections and found that administration of bevacizumab resulted in a greater decrease in macular thickness in the untreated eye of patients with bilateral DME [14].

This result suggests that the longer systemic half-life of bevacizumab versus ranibizumab may be causing the greater reduction in fellow eye retinal thickness [15]. However, aflibercept has a similar systemic half-life as that of bevacizumab and both are reported to cause significant reduction of plasma VEGF for transient windows as long as 4 weeks after intravitreal delivery, and longer than the effect exerted by ranibizumab [16-18]. Despite this, markedly fewer reports of fellow eye response to unilateral aflibercept have been reported [8,9].

Conclusion

This case serves as an important reminder, in particular as newer agents with even greater VEGF-inhibitory capacity and/or half-life are developed, to remain vigilant of the systemic effects of our “local” treatment.

Conflict of Interest

The authors declare that they do not have any financial interest or conflict of interest.

Bibliography


